EGFR and non-small cell lung carcinoma: The large number of anticancer drugs administered after postoperative relapse may be attributed to the large number of treatment options for first‐ and subsequent‐line treatments of NSCLC, including platinum‐based combination regimens, cytotoxic drug monotherapy, ICIs, and EGFR‐TKIs (gefitinib, erlotinib, afatinib, and osimertinib) (Table 2).